Key result
Focal Purkinje trigger ablation in HCM is linked to ~80% freedom from primary VF.
Why the study?
The origin of ventricular fibrillation and the success of catheter ablation to eliminate recurrent episodes in patients with hypertrophic cardiomyopathy are poorly understood.
Does radiofrequency ablation of Purkinje triggers prevent recurrent ventricular fibrillation in patients with hypertrophic cardiomyopathy?
Observational (n=5)
No
Does radiofrequency ablation of Purkinje triggers prevent recurrent ventricular fibrillation in patients with hypertrophic cardiomyopathy?
Focal radiofrequency ablation of Purkinje triggers in patients with hypertrophic cardiomyopathy is associated with a marked reduction in recurrent ventricular fibrillation burden.
Hypothesis-generating for Purkinje ablation in select HCM-VF cases; leaves open confirmation in prospective trials.
INTRODUCTION: Ventricular fibrillation (VF) is the main mechanism of sudden cardiac death in patients with hypertrophic cardiomyopathy (HCM). The origin of VF and the success of catheter ablation to eliminate recurrent episodes in this population are poorly understood. METHODS AND RESULTS: From 2010 to 2014, five patients with HCM (age 21 ± 9 years, three female) underwent invasive electrophysiological studies and ablation at our center after resuscitation from recurrent (9 ± 7) episodes of VF. Ventricular premature beats (VPBs), seen to initiate VF in certain cases, were recorded noninvasively before the ablation procedure. Postprocedural computed tomography (CT) was performed to correlate ablation sites with myocardial hypertrophy in three patients. Outcomes were assessed by clinical follow-up and implantable cardioverter-defibrillator interrogations. VPB triggers were localized invasively to the distal left Purkinje conduction system (left posterior fascicle [2], left anterior fascicle [1], and both fascicles [2]). All targeted VF triggers were successfully eliminated by radiofrequency ablation in the left ventricle. Among patients with postablation CT imaging, 93 ± 12% of ablation sites corresponded to hypertrophied segments. Over 50 ± 38 months, four of five patients were free from primary VF without antiarrhythmic drug therapy. One patient who had 13 episodes of VF before ablation had a single recurrence. CONCLUSION: In our study of patients with HCM and recurrent VF, VF was not initiated from the myocardium but rather from Purkinje arborization. These sources colocalized with the hypertrophic substrate, suggesting electromechanical interaction. Focal ablation at these sites was associated with a marked reduction in VF burden.
No takes yet. Share an insight, caveat, or question.
Hocini et al. (2021) conducted an observational in Hypertrophic cardiomyopathy with recurrent ventricular fibrillation (n=5). Radiofrequency catheter ablation of Purkinje triggers was evaluated on Freedom from primary VF without antiarrhythmic drug therapy. Focal radiofrequency ablation of Purkinje triggers in patients with hypertrophic cardiomyopathy and recurrent ventricular fibrillation resulted in 80% of patients remaining free from primary VF.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: